Simplex Trading’s Seelos Therapeutics, Inc. Common Stock SEEL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q4
Sell
-112
Closed -$78K 10094
2023
Q3
$78K Buy
112
+30
+37% +$129K ﹤0.01% 5359
2023
Q2
$375K Buy
82
+21
+34% +$72.9K ﹤0.01% 3604
2023
Q1
$162K Sell
61
-23
-27% -$67.3K ﹤0.01% 4576
2022
Q4
$218K Sell
84
-1
-1% -$3.49K ﹤0.01% 4126
2022
Q3
$334K Buy
85
+16
+23% +$62.9K ﹤0.01% 3945
2022
Q2
$181K Buy
69
+45
+188% +$117K ﹤0.01% 4738
2022
Q1
$75K Buy
24
+17
+243% +$73.1K ﹤0.01% 6563
2021
Q4
$41K Sell
7
-5
-42% -$38.4K ﹤0.01% 7512
2021
Q3
$130K Sell
12
-3
-20% -$25.8K ﹤0.01% 6250
2021
Q2
$151K Buy
+15
New +$246K ﹤0.01% 6125
2021
Q1
Hold
0
6815

Other funds holding SEEL

Simplex Trading's SEEL Position: Q2 2022 in Review

Simplex Trading sold out of Seelos Therapeutics, Inc. Common Stock (SEEL) in Q2 2022, closing a stake of 64 shares — an estimated $167K sold.

Simplex Trading first reported a position in SEEL in Q1 2021 and held it in 5 quarters. The position peaked at $315K in Q4 2021. 65 funds tracked by Wall St. Rank hold SEEL as of Q2 2022.

  • Simplex Trading reported no remaining Seelos Therapeutics, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
  • Simplex Trading sold 64 Seelos Therapeutics, Inc. Common Stock shares in Q2 2022, an estimated $167K.
  • Simplex Trading first reported a position in Seelos Therapeutics, Inc. Common Stock in Q1 2021 and held it in 5 quarters.
  • Simplex Trading's Seelos Therapeutics, Inc. Common Stock position peaked at $315K in Q4 2021.
  • 65 funds tracked by Wall St. Rank held Seelos Therapeutics, Inc. Common Stock as of Q2 2022.

Based on Simplex Trading's 13F filing for Q2 2022, filed 3 Aug 2022.